サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1788278

肺がん検診ソフトウェアの世界市場

Lung Cancer Screening Software

出版日
ページ情報
英文 98 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.66円
肺がん検診ソフトウェアの世界市場
出版日: 2025年08月12日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 98 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

肺がん検診ソフトウェアの世界市場は2030年までに4,050万米ドルに達する見込み

2024年に2,840万米ドルと推定される肺がん検診ソフトウェアの世界市場は、2030年には4,050万米ドルに達し、分析期間2024-2030年のCAGRは6.1%で成長すると予測されます。

米国市場は750万米ドルと推定、中国はCAGR6.0％で成長予測

米国の肺がん検診ソフトウェア市場は2024年に750万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに650万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.7％と5.2％と予測されています。欧州では、ドイツがCAGR 4.9%で成長すると予測されています。

肺がん検診ソフトウェアの世界市場- 早期発見・診断に革命をもたらす

肺がん検診ソフトウェアが人気を集める理由とは？

肺がんは、がん関連死亡の世界の主要原因の1つであり、発見が遅れたことによる死亡率が高いです。早期診断により生存率は大幅に向上し、肺がん検診ソフトウェアは発見精度と効率を高める重要なツールとして台頭しています。医療用画像診断における人工知能（AI）や機械学習（ML）の採用は、放射線科医や腫瘍医がより高い精度で肺結節を特定するのに役立つため、市場を牽引しています。長期喫煙者などの高リスク集団を対象とした政府の取り組みや検診プログラムが、高度な検診ソリューションの需要をさらに押し上げています。肺がん検診ソフトウェアが病院の放射線部門や遠隔医療プラットフォームに統合されつつあることで、早期発見がより身近で効果的なものとなっています。

イノベーションはどのように肺がん検診ソフトウェアの性能を高めていますか？

AI駆動アルゴリズムとディープラーニングモデルの統合により、肺がん検診ソフトウェアの精度が大幅に向上しています。これらの技術は、小さな結節も検出することで画像解析を強化し、診断における偽陽性や偽陰性を低減します。クラウドベースの検診プラットフォームと遠隔医療統合により、特に遠隔地や十分なサービスを受けていない地域での検診サービスへのアクセスが拡大しています。予測分析の採用は、医師が患者の危険因子を評価し、さらなる評価のために高リスク症例の優先順位をつけるのに役立っています。さらに、肺がん検診ソフトウェアと電子カルテ（EHR）を組み合わせることで、ワークフローの効率が合理化され、リアルタイムのデータ分析と自動レポート作成が可能になります。

市場促進要因は？

肺がん検診ソフトウェア市場の成長を後押ししている要因はいくつかあります。肺がんの有病率の上昇と早期発見の重視の高まりが主要な促進要因です。特に先進国では、肺がん検診プログラムを支援する政府の規制とヘルスケア政策が採用率を加速させています。ヘルスケアにおけるAIと自動化の利用の拡大、デジタルヘルス技術への投資の増加は、洗練されたスクリーニングソリューションの需要をさらに押し上げています。さらに、クラウドベースの医療用画像処理プラットフォームの拡大や、ソフトウェア開発者とヘルスケアプロバイダーとの協業の増加が市場開拓に寄与しています。

課題と将来機会は？

肺がん検診ソフトウェア市場は、その可能性にもかかわらず、高い導入コスト、データプライバシーに関する懸念、既存のヘルスケアITシステムとの相互運用性の問題などの課題に直面しています。また、手作業による画像解析に依存している従来の放射線科医からの抵抗も、採用を遅らせる可能性があります。しかし、AI支援診断の受け入れの拡大、より費用対効果の高いクラウドベースのソリューションの開発、法規制遵守の進展により、大きなビジネスチャンスが生まれています。今後の市場成長の原動力となるのは、AIを活用したリアルタイム診断、遺伝的要因やライフスタイル要因に基づく個別化検診プロトコル、肺がん検診ソフトウェアのモバイルヘルスアプリケーションへの統合です。

セグメント

単一セグメント

調査対象企業の例

  • C the Signs
  • Canon Medical Systems Corporation
  • Dxcover Ltd
  • Eon
  • FUJIFILM Holdings Corporation
  • Guardant Health
  • iDNA
  • ITK-SNAP
  • Koninklijke Philips N.V.
  • MagView
  • Medtronic
  • MRS Systems, Inc.
  • Nuance Communications, Inc.
  • Oatmeal Health
  • Optellum
  • PenRad Technologies, Inc.
  • Siemens Healthineers AG
  • Thynk Health
  • Volpara Health
  • VoxelCloud

AIインテグレーション

私たちは、検証された専門家のコンテンツとAIツールによって、市場と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP31929

Global Lung Cancer Screening Software Market to Reach US$40.5 Million by 2030

The global market for Lung Cancer Screening Software estimated at US$28.4 Million in the year 2024, is expected to reach US$40.5 Million by 2030, growing at a CAGR of 6.1% over the analysis period 2024-2030.

The U.S. Market is Estimated at US$7.5 Million While China is Forecast to Grow at 6.0% CAGR

The Lung Cancer Screening Software market in the U.S. is estimated at US$7.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.5 Million by the year 2030 trailing a CAGR of 6.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.7% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Lung Cancer Screening Software Market - Revolutionizing Early Detection and Diagnosis

Why Is Lung Cancer Screening Software Gaining Popularity?

Lung cancer is one of the leading causes of cancer-related deaths worldwide, with a high mortality rate due to late-stage detection. Early diagnosis significantly improves survival rates, and lung cancer screening software is emerging as a crucial tool in enhancing detection accuracy and efficiency. The adoption of artificial intelligence (AI) and machine learning (ML) in medical imaging is driving the market, as these technologies help radiologists and oncologists identify lung nodules with greater precision. Government initiatives and screening programs aimed at high-risk populations, such as long-term smokers, are further propelling the demand for advanced screening solutions. The increasing integration of lung cancer screening software into hospital radiology departments and telemedicine platforms is making early detection more accessible and effective.

How Are Innovations Enhancing the Performance of Lung Cancer Screening Software?

The integration of AI-driven algorithms and deep learning models is significantly improving the accuracy of lung cancer screening software. These technologies enhance image analysis by detecting even the smallest nodules, reducing false positives and false negatives in diagnosis. Cloud-based screening platforms and telemedicine integration are expanding access to screening services, particularly in remote and underserved areas. The adoption of predictive analytics is helping physicians assess patient risk factors and prioritize high-risk cases for further evaluation. Additionally, the combination of lung cancer screening software with electronic health records (EHRs) is streamlining workflow efficiency, allowing for real-time data analysis and automated reporting.

What Are the Key Market Drivers?

Several factors are fueling the growth of the lung cancer screening software market. The rising prevalence of lung cancer and the increasing emphasis on early detection are key drivers. Government regulations and healthcare policies supporting lung cancer screening programs, particularly in developed nations, are accelerating adoption rates. The growing use of AI and automation in healthcare, along with increasing investments in digital health technologies, is further boosting the demand for sophisticated screening solutions. Additionally, the expansion of cloud-based medical imaging platforms and the increasing collaboration between software developers and healthcare providers are contributing to market growth.

What Challenges and Future Opportunities Exist?

Despite its potential, the lung cancer screening software market faces challenges such as high implementation costs, data privacy concerns, and interoperability issues with existing healthcare IT systems. Resistance from traditional radiologists who rely on manual image analysis may also slow down adoption. However, the growing acceptance of AI-assisted diagnostics, the development of more cost-effective cloud-based solutions, and advancements in regulatory compliance are creating significant opportunities. Future growth in the market will be driven by AI-powered real-time diagnosis, personalized screening protocols based on genetic and lifestyle factors, and the integration of lung cancer screening software into mobile health applications.

SCOPE OF STUDY:

The report analyzes the Lung Cancer Screening Software market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Single Segment

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

  • C the Signs
  • Canon Medical Systems Corporation
  • Dxcover Ltd
  • Eon
  • FUJIFILM Holdings Corporation
  • Guardant Health
  • iDNA
  • ITK-SNAP
  • Koninklijke Philips N.V.
  • MagView
  • Medtronic
  • MRS Systems, Inc.
  • Nuance Communications, Inc.
  • Oatmeal Health
  • Optellum
  • PenRad Technologies, Inc.
  • Siemens Healthineers AG
  • Thynk Health
  • Volpara Health
  • VoxelCloud

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Lung Cancer Screening Software - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Lung Cancer Incidence Rates Throws the Spotlight on Early Detection and Screening Solutions
    • Growing Emphasis on Precision Medicine Propels Demand for AI-Driven Lung Cancer Screening Software
    • Increasing Government-Led Screening Programs Expands Addressable Market Opportunity for Lung Cancer Detection Tools
    • Escalating Awareness Campaigns on Smoking Risks Drives Adoption of Preventive Screening Technologies
    • Advancements in AI and Deep Learning Algorithms Strengthen the Business Case for Automated Lung Nodule Detection
    • Integration of Lung Cancer Screening Software into Radiology Workflows Accelerates Demand Among Hospitals and Imaging Centers
    • Cloud-Based Diagnostic Platforms Sustain Growth in Remote Screening and Teleradiology Markets
    • Reimbursement Reforms and Coverage Expansion in Developed Markets Drive Commercial Adoption
    • Surge in Geriatric Population at High Risk of Lung Cancer Spurs Demand for Preventive Screening Tools
    • Rapid Uptake of Low-Dose CT (LDCT) in Routine Clinical Practice Fuels Growth of Compatible Screening Software
    • Expansion of National Screening Guidelines Across Key Markets Boosts Software Deployment
    • Enhanced Image Processing Capabilities and 3D Visualization Drives Market Penetration in Oncology Imaging
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Lung Cancer Screening Software Market Analysis of Annual Sales in US$ for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Lung Cancer Screening Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Lung Cancer Screening Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Lung Cancer Screening Software Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 5: USA Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 6: USA Historic Review for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • CANADA
    • TABLE 7: Canada Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 8: Canada Historic Review for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • JAPAN
    • Lung Cancer Screening Software Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 9: Japan Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 10: Japan Historic Review for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • CHINA
    • Lung Cancer Screening Software Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 11: China Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 12: China Historic Review for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • EUROPE
    • Lung Cancer Screening Software Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 13: Europe Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 14: Europe Historic Review for Lung Cancer Screening Software by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 15: Europe 15-Year Perspective for Lung Cancer Screening Software by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
    • Lung Cancer Screening Software Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 16: France Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 17: France Historic Review for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • GERMANY
    • Lung Cancer Screening Software Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 18: Germany Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 19: Germany Historic Review for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • ITALY
    • TABLE 20: Italy Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Italy Historic Review for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • UNITED KINGDOM
    • Lung Cancer Screening Software Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 22: UK Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 23: UK Historic Review for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • REST OF EUROPE
    • TABLE 24: Rest of Europe Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Rest of Europe Historic Review for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • ASIA-PACIFIC
    • Lung Cancer Screening Software Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 26: Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Asia-Pacific Historic Review for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • REST OF WORLD
    • TABLE 28: Rest of World Recent Past, Current & Future Analysis for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Rest of World Historic Review for Lung Cancer Screening Software by Segment - Lung Cancer Screening Software Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR

IV. COMPETITION